We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current SRBZF market cap is 886.98M. The company's latest EPS is EUR 1.0748 and P/E is 67.88.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 222.09M | 256.25M | 287.34M | 274.63M | 261.91M |
| Operating Income | 20.25M | 35.01M | 49.4M | 42.75M | 25.44M |
| Net Income | 14.44M | 25.18M | 39.96M | 29.22M | 13.07M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 299.41M | 331.9M | 368.53M | 397.5M | 466.58M |
| Total Liabilities | 140.41M | 159.36M | 162.77M | 172.32M | 233.25M |
| Total Equity | 159.01M | 172.55M | 205.76M | 225.18M | 233.33M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | 21.26M | 31.85M | 63.47M | 10.28M | 19.43M |
| Investing | -27.72M | -21.85M | -20.13M | -19M | -44.16M |
| Financing | 5.45M | 5.22M | -34.33M | -14.11M | 35.44M |
| Market Cap | 886.98M |
| Price to Earnings Ratio | 67.88 |
| Price to Sales Ratio | 3.39 |
| Price to Cash Ratio | 26.45 |
| Price to Book Ratio | 3.8 |
| Dividend Yield | - |
| Shares Outstanding | 12.16M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 5 (9.17%) |
| Company Name | STRATEC Biomedical Systems AG (PK) |
| Address |
gewerbestrasse 37 birkenfeld 75217 |
| Website | https://www.stratec.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
